The Winner of the 2007 EUROPEAN BIOTECHNICA AWARD is the Renovo Group from the United Kingdom

    --  Second Place Goes to Genmab A/S, Denmark

    --  In Third Place is Bavarian Nordic A/S, Denmark

    HANNOVER, GERMANY, October 9 /CNW/ - Renovo Group Plc from Manchester has
good reason to celebrate. This evening the British manufacturer of
biopharmaceuticals was awarded first prize in the 2007 EUROPEAN BIOTECHNICA
AWARD at the official opening ceremony for BIOTECHNICA in Hannover. In second
place was the biotech company Genmab A/S from Copenhagen. And third place went
to another Danish company, Bavarian Nordic A/S, which manufactures
biopharmaceutical products in Kvistgaard. Christian Wulff, the Premier of
Lower Saxony, Dr. Karl-Ludwig Kley, Chairman of the Board of Merck KGaA,
Christian Siebert, departmental head at the European Commission, and Stephan
Ph. Kuhne, who sits on the Board of Management at Deutsche Messe AG, Hannover,
presented the prizes in the presence of more than 500 invited persons from the
worlds of science, business and politics.

    This was the fifth successive year in which Deutsche Messe has awarded
the prize - now worth a total of 100,000 euros - to European companies working
in biotechnology and the life sciences which have developed particularly
innovative products, services and associated business ideas. "We noted this
year an increase in the number of competition entrants, particularly from
countries outside Germany. This is a clear indicator of the growing importance
of the biotechnology industry as a driver of economic growth," says Stephan

    The international jury, made up of distinguished biotech experts from six
countries, selected the three winners from a list of 27 applicants. The
criteria for the award were market viability, market relevance, market
presence of products and services, and a promising marketing concept.

    First prize goes to Renovo Group Plc from the United Kingdom

    Renovo researches and develops biopharmaceutical products for the
preventive treatment and reduction of scarring. "The winner Renovo impressed
the jury with its high scientific standards, its pioneering products in a very
important area of application that has hitherto suffered from low standards of
treatment, its strong financial situation and its genuine entrepreneurial
spirit," comments Professor Dr. Peter J. W. Stadler in his capacity as jury

    Renovo receives 20,000 euros in cash. In addition the company will
receive substantive benefits in the form of an exhibition stand at BIOTECH
CHINA 2008 in Shanghai (28 to 30 May), an IPO welcome pack from the German
Stock Exchange, a media package in the "European Biotechnology News" and a
year's membership of the European umbrella association for the biotechnology
industry, EuropaBio, in Brussels.

    Genmab A/S and Bavarian Nordic A/S in second and third place respectively

    The second-placed contender Genmab from Denmark develops human antibodies
for the treatment of life-threatening and debilitating diseases. "Genmab is
remarkable for its outstanding technological base, which has been used to
build up a very strong portfolio of development products, as well as for its
extraordinary ability to transmute all this into financial success for the
company," observes Stadler.

    Third place went to the Danish company Bavarian Nordic A/S. This company
develops and manufactures innovative vaccines for the prevention and treatment
of infectious diseases and cancer. "Bavarian commended itself to the jury by
its presentation of an impressive raft of vaccines currently under
development, a clear focus on applications and a strong financial basis,"
explains Stadler.

    The main prizes for the second-placed and third-placed companies
respectively consist of a ten-day and five-day consultancy course with
consultants Capgemini, with the focus on business strategy and investment. In
addition, both companies will each receive a media package in the "European
Biotechnology News" and a year's membership of the European umbrella
association for the biotechnology industry, EuropaBio, in Brussels.

    The presentation of the fifth EUROPEAN BIOTECHNICA AWARD marks the formal
opening of BIOTECHNICA 2007, which takes place from 9 to 11 October 2007 at
the Hannover Exhibition Grounds. 863 exhibitors from 32 nations will be
presenting their latest products and developments from right across the
biotechnology spectrum.

    Information about previous prize-winners and the terms of entry for the
next competition can be found online at

    Additional press releases and photos can be found at


    5th International Prize for European companies working in biotechnology
and the life sciences

    The following competition entrants were presented with the 2007 EUROPEAN
BIOTECHNICA AWARD on Monday 8 October 2007 in Hannover.

    Bavarian Nordic A/S, B0geskovvej 9, 3490 Kvistgaard, Denmark

    Bavarian Nordic is a leading international biopharmaceutical company
developing and producing innovative vaccines to prevent and treat infectious
diseases and cancer. With operations in Denmark, Germany, the USA, and
Singapore, Bavarian Nordic employs over 230 people.

    Bavarian Nordic's patented technology, MVA-BN(R), is, as has been
demonstrated in clinical studies, one of the world's safest, multivalent
vaccine vectors for the development of vaccines against various infectious
diseases such as smallpox, HIV/AIDS, as well as against breast and prostate
cancer. Several MVA-BN(R)-based HIV and smallpox vaccines are in clinical
Phase I and Phase II trials.

    Bavarian Nordic has supplied several governments with smallpox vaccines
and, with its increased production capacity, is able to supply the growing
demand, particularly for safe smallpox vaccines. With a global manufacturing
capacity consisting of its new state-of-the-art production facility in Denmark
(minimum capacity of 40 million doses per year that can be expanded to 180
million doses per year), and an ongoing partnership with the German vaccine
producer, Impfstoffwerk Dessau-Tornau (IDT), Bavarian Nordic has ensured
supply of its current and future vaccines.

    Genmab A/S, Toldbodgade 33, 1253 Copenhagen, Denmark

    Genmab A/S is an international biotechnology company that is developing
fully human antibodies to treat life-threatening and debilitating diseases.
The company uses the most advanced technology available to develop antibodies
in an effort to make products designed to help patients who are suffering from
diseases for which treatment does not work, or does not exist. Genmab has
developed a broad pipeline of 38 potential antibody products in a variety of
disease areas, including 6 in clinical development and 18 in pre-clinical

    The internal pre-clinical development team selects the best antibody
candidates and the clinical development team moves these candidates through
clinical studies as rapidly and efficiently as possible. In addition, Genmab
in-licenses potential targets from other biotechnology and pharmaceutical
companies to further expand its product pipeline. Genmab chooses to develop
some of its products in-house through late-stage development, while
out-licensing some other products to other companies. This strategy serves
both to balance risk and facilitate the pursuit of further development
opportunities. The combination of streamlined development teams, cutting-edge
technology, international clinical and regulatory expertise, diversified
product pipeline and solid financial and managerial foundation has given
Genmab a tremendous edge over its competitors and has helped establish the
company as a leader in the biotechnology industry.

    Renovo Group Plc., Grafton Street 48, M13 9XX Manchester, United Kingdom

    Renovo is a biopharmaceutical product company and is the world leader in
scar prevention and reduction research and the development of drugs to prevent
and reduce scarring. The Company has a highly skilled management team with
over 30 years of research experience in the field of scarring and significant
pharmaceutical industry expertise. Scarring can result from acute injury in,
or surgery to, the skin, blood vessels, eyes, nerves, internal organs, tendons
and ligaments. These are high value markets of significant unmet medical need.

    Renovo has a portfolio of drugs which exploit different novel mechanisms
of action to prevent and reduce scarring at multiple body sites and to
accelerate healing. This deep pipeline includes one drug that has recently
initiated Phase III clinical development in December 2006; three drugs in
Phase II clinical development; a further four advanced pre-clinical
candidates; and 15 other pre-clinical candidates.

    Renovo's research and development approach is to focus on the drug
development stage and to direct activities towards gaining early indications
of efficacy in humans. A deep understanding of the mechanisms of scarring has
enabled Renovo to select a range of candidates and programmes based on
different mechanisms of action which, as they are relatively independent of
one another, give robustness to the Group's pipeline. Renovo's pipeline
derives both from in-house research and from external collaborations with
selected academic groups worldwide.

    Renovo aims to be first to the market with a pharmaceutical drug in the
US and Europe to prevent and reduce scarring. Current demand is inadequately
met and there is no near term competition. According to external research, the
potential commercial market for prevention and reduction of scarring in the
skin is worth $4 billion per annum in the US alone.

    The jury:

    --  Professor Dr. Peter J. W. Stadler, CEO, ARTEMIS Pharmaceuticals GmbH,
Cologne, Germany (Chairman)

    --  Dr. Luca Benatti, founder and CEO, Newron Pharmaceuticals SPA,
Bresso, Italy

    --  Professor Dr. Horst Domdey, Chairman of the Board at BioM,
Martinsried, Germany

    --  Professor Dr. Oreste Ghisalba, Novartis Pharma AG, Basle, Switzerland

    --  Michel Greco, expert on vaccines and former president of Aventis
Pasteur SA, Paris, France

    --  Dr. Karsten Henco, founder of Qiagen and Evotec, as well as CEO of U3
Pharma AG, Martinsried, Munich, Germany

    --  Professor. Dr. Karl Kuchler, Head of the Institute of Medical
Biochemistry, Vienna University, Austria

    --  Dr. Philippe Pouletty, founder and CEO of Truffle Venture, as well as
President of France Biotech, Paris, France

    --  Professor Dr. Rolf G. Werner, Managing Director Biopharmaceuticals,
Boehringer Ingelheim GmbH, Biberach, Germany

    --  Professor Dr. Roland Wolf, Director of Science CXR Biosciences as
well as head of the Biomedical Research Centre, University of Dundee, United

For further information:

For further information: Deutsche Messe AG for BIOTECHNICA Katharina
Siebert, +49 (0)511 89-31028

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890